The Society of Nuclear Medicine and Molecular Imaging and the European Association of Nuclear Medicine have updated the clinical indications for PSMA-ligand PET/CT, which now include the initial staging of intermediate-to high-risk PCa, localization of metastatic disease in BCR or persistent PCa cases, and response assessment before and after RLT [50,51]. This evidence concerns the gene FOLH1 and metastatic neoplasm.